We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

45 hedge funds and large institutions have $265M invested in Relmada Therapeutics in 2019 Q4 according to their latest regulatory filings, with 45 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

42,500% more call options, than puts

Call options by funds: $2.13M | Put options by funds: $5K

47.8% more ownership

Funds ownership: 0% → 47.8% (+48%)

Holders
45
Holders Change
+45
Holders Change %
–
% of All Funds
0.89%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
45
Increased
–
Reduced
–
Closed
–
Calls
$2.13M
Puts
$5K
Net Calls
+$2.13M
Net Calls Change
+$2.13M

Top Buyers

1
TCM
Tang Capital Management
California
+$39.5M
2
VMI
VHCP Management III
New York
+$23.3M
3
RCM
RA Capital Management
Massachusetts
+$23.1M
4
RI
RTW Investments
New York
+$20.2M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$17.3M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
ECM
26
ExodusPoint Capital Management
New York
$458K +$357K +11,755 New
Wells Fargo
27
Wells Fargo
California
$396K +$309K +10,159 New
APM
28
Avidity Partners Management
Texas
$390K +$304K +10,000 New
Squarepoint
29
Squarepoint
New York
$348K +$271K +8,918 New
CIP
30
Chartwell Investment Partners
Pennsylvania
$342K +$267K +8,780 New
MA
31
MYDA Advisors
New York
$273K +$213K +7,000 New
Morgan Stanley
32
Morgan Stanley
New York
$263K +$205K +6,748 New
TD Asset Management
33
TD Asset Management
Ontario, Canada
$253K +$197K +6,493 New
BBHC
34
Brown Brothers Harriman & Co
New York
$234K +$182K +6,000 New
Goldman Sachs
35
Goldman Sachs
New York
$211K +$164K +5,413 New
UBS Group
36
UBS Group
Switzerland
$166K +$129K +4,257 New
TIM
37
Tortoise Investment Management
New York
$113K +$88.1K +2,900 New
TRCT
38
Tower Research Capital (TRC)
New York
$84K +$65.1K +2,143 New
Simplex Trading
39
Simplex Trading
Illinois
$83K +$65K +2,140 New
Citigroup
40
Citigroup
New York
$37K +$28.4K +936 New
NFG
41
Next Financial Group
Texas
$12K +$9.3K +306 New
LTFS
42
Ladenburg Thalmann Financial Services
Florida
$7K +$5.32K +175 New
PCM
43
Prelude Capital Management
New York
$5K +$3.68K +121 New
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$1K +$1.09K +36 New
GEA
45
Glen Eagle Advisors
New Jersey
$975 +$760 +25 New
1
2

RLMD Hedge Fund Activity: Q4 2019 in Review

45 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q4 2019, worth a combined $265M.

Buyers outnumbered sellers: 45 funds opened new RLMD positions and 0 closed out — a net gain of 45 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $39.5M.

  • 45 institutional investors held Relmada Therapeutics (RLMD) as of Q4 2019, up from 0 in Q3 2019.
  • Funds reported $265M of Relmada Therapeutics stock for Q4 2019.
  • 45 funds opened new Relmada Therapeutics positions in Q4 2019 and 0 closed out, a net change of +45 holders.
  • The largest Relmada Therapeutics buyer in Q4 2019 was Tang Capital Management, an estimated $39.5M added.

Based on aggregated 13F filings for Q4 2019.